Brain Tumor Related Epilepsy (BTRE) is a multi-factorial condition with unclear pathophysiology. It has a robust prevalence in tumor patients with 20-40% experiencing onset seizures and a further 20-45% experiencing refractory seizures to treatment.1 This work examines the tumor microenvironment using magnetic resonance spectroscopy (MRS) to learn more about the epileptogenic mechanisms through a comparison of metabolite composition in BTRE patients and non-seizure tumor patients. Increasing knowledge about the pathophysiology of BTRE might aid the management of anti-tumor and BTRE treatment in the future.
No takes yet. Share an insight, caveat, or question.
Najam et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: